Recent news from The Wall Street Journal has become a significant milestone for Novavax Inc. $NVAX, a company engaged in the development of COVID-19 vaccines. According to the report, U.S. regulatory agencies have requested that the company conduct yet another clinical trial of its vaccine. This information negatively impacted the stock market, leading to a sharp 13% decline in the company’s shares on Friday.

Shares of Novavax Inc. have dropped significantly by 26% following recent statements made by U.S. Secretary of Health and Human Services Robert F. Kennedy Jr., who expressed doubts about the efficacy of the company’s COVID-19 vaccine. This development has caught the attention of both investors and health experts alike.